Repare Therapeutics Acquired by XenoTherapeutics

Repare Therapeutics, a biotechnology firm, is set to be acquired by XenoTherapeutics in a deal that could provide future cash payments from existing partnerships and product candidates. The acquisition, valued at approximately $2.82 per share, is expected to finalize in the first quarter of 2026. Repare recently reported a significant increase in revenue and net income for the third quarter of 2025, ending the quarter with a strong cash position. The company also shared positive initial data from its Phase One clinical trial for a new cancer treatment.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.